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ABSTRACT  
Data on all outpatient opioid prescriptions (N=71,647) to youth below age 21 (N=42,020) 
from 2005-2016 were extracted from electronic medical records within a university 
hospital system, including demographic characteristics, markers of morbidity, and 
mortality. Relative risk was calculated for markers of morbidity and mortality based on 
sociodemographic characteristics. The sample was primarily male (55.0%), 
Hispanic/Latino (50.1%), English-speaking (88.9%), and publicly insured(50.1%). Mean 
age was 13.54 (sd = 6.50). From 2005-2016, overall frequency of opioid prescriptions 
increased by 86.6% (from 2470 to 4610) with the largest increase (206.2%) observed 
from 2005-2008 (2470 to 7562). Patients who were older, White, and Non-Hispanic were 
more likely to receive multiple opioid prescriptions. Large increases in opioid-related 
morbidity and mortality were documented, although base-rates remained low. 
Significantly increased risk of adverse outcomes was observed in patients receiving 
multiple opioid prescriptions, and in patients who were older, of minority race, and 
publicly insured or uninsured.  
 
.  
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Chapter 1 
Introduction  
Problematic opioid use and subsequent adverse consequences, including opioid-related 
overdose deaths, are well-documented public health concerns in the United States (US). 
These concerns are partially fueled by the dramatic increase in rates of opioid 
prescriptions and community availability of prescription opioids over recent decades 
(Manchikanti, Fellows, Ailinani, & Pampati, 2010; Shaheed, Maher, Williams, Day, & 
Mclachlan, 2016; Vowles et al., 2015). In adults, drug overdose is the leading cause of 
accidental death, whereby 60-70% of prescription drug overdose deaths can be accounted 
for by prescribed opioids (Centers for Disease Control and Prevention National Center 
for Health Statistics, 2015; Jones, Mack, & Paulozzi, 2013; Rudd, Aleshire, Zibbell, & 
Gladden, 2016; Vowles et al., 2015) and opioid-related overdose deaths are decreasing 
the life expectancy of Americans (Kochanek, Murphy, Xu, & Arias, 2017).  Further, 
opioid misuse, defined as “opioid use contrary to the directed or prescribed pattern of use, 
regardless of the presence or absence of harm or adverse effects” (Vowles et al., 2015, p. 
570) is associated with increased heroin use (Carlson, Nahhas, Martins, & Daniulaityte, 
2016) among other adverse consequences (e.g. overdose).  
While these issues are relatively well characterized in adults, opioid prescribing 
trends and implications remain unclear in children, adolescents, and young adults 
(Schechter, 2014). Results from published national studies examining opioid prescribing 
rates to youth in the last two decades vary greatly, with some data indicating little to no 
significant change (Groenewald, Rabbitts, Gebert, & Palermo, 2015), while others report 
increases of 40%-100% (Fortuna, Robbins, Caiola, Joynt, & Halterman, 2010; Mazer-
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Amirshahi, Mullins, Rasooly, van den Anker, & Pines, 2014; Sheridan et al., 2016). 
Nonetheless, opioids are a part of standard treatment for painful conditions in youth, such 
as traumatic injuries, post-surgical pain management, cancer, and dental care 
(Groenewald et al., 2015; Walco, Gove, Phillips, & Weisman, 2017). 
Although prescription trends in youth are uncertain, two things are clear; both of 
which shadow trends in adults: 1) youth are misusing opioids, and 2) problematic opioid 
use among youth is associated with substantial risk of morbidity and mortality. In 2016, 
1.7% of persons age 12 or older initiated illicit drug use with pain relievers, which was 
more than initiation rates of all other illicit drugs, aside from marijuana (Substance Abuse 
and Mental Health Services Administration, 2017). Findings from the 2015 National 
Survey on Drug Use and Health revealed that pain relievers, typically opioids, were the 
most widely used psychotherapeutic drug among persons above the age of 12 (Center for 
Behavioral Health Statistics and Quality, 2016), with leftover prescriptions repeatedly 
identified as a primary source for nonmedical use (Binswanger & Glanz, 2015; McCabe, 
West, & Boyd, 2013a; Voepel-Lewis, Wagner, & Tait, 2015). More specifically, in 2016, 
approximately 3.6% of adolescents (n~891,000 age 12 to 17 years) and 7.3% of young 
adults (n=~2.5 million age 18 to 25) reported current misuse of prescription pain 
relievers. Further, it is estimated that .6% of adolescents and 1.1% of young adults had an 
opioid use disorder in 2016 (Substance Abuse and Mental Health Services 
Administration, 2017).  
Nonmedical use of prescription opioids in childhood has also been identified as a 
strong predictor of initiating heroin use during adolescence (Cerdá, Santaella, Marshall, 
Kim, & Martins, 2015; Palamar, Shearston, Dawson, Mateu-Gelabert, & Ompad, 2016). 
Of greater concern, deaths from prescription drug overdoses in youth doubled from 2001 
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to 2014 (Center for Disease Control & National Center for Health Statistics, 2015), as did 
inpatient admissions due to opioid poisoning from 1997 to 2012 (Gaither, Leventhal, 
Ryan, & Camenga, 2016). In 2015, drug-related death rates for youth age 15-19 in the 
United States was highest for opioids, especially heroin (Curtain, Tejada-Vera, & 
Warner, 2017).  Recent data also reflect an association between national rates of opioid 
prescribing to adolescents and rates of adolescent calls to poison centers regarding opioid 
ingestions (Sheridan et al., 2016). 
Further, evidence has shown that adolescents tend to underestimate the potential 
risk of taking prescription opioids (Martin, Bhalla, Beltran, Veneziano, & Tobias, 2014), 
with one study reporting that 41% of adolescents perceived prescription drugs to be safer 
than illegal drugs and almost a third (29%) believed that prescription pain relievers were 
not addictive (Martin et al., 2014). Finally, exposure to opioids as an adolescent appears 
to present a risk for problematic opioid use as an adult. A longitudinal study, using data 
from the Centers for Disease Control (CDC) Monitoring the Future study (The Regents 
of the University of Michigan, 2016), found a significant association between both 
medical and nonmedical use of prescription opioids during adolescence and subsequent 
non-medical use of opioids when participants were 35 years of age (McCabe, Veliz, & 
Schulenberg, 2016). Additional work in this area found that adolescents who self-
reported medical and nonmedical opioid use were more likely to engage in medical use 
before nonmedical use (McCabe et al., 2017). In other words, any exposure to opioids 
(e.g. medical or non-medical) during adolescence may carry with it potential for short 
and long-term risk. 
Individual Factors Associated with Receiving an Opioid Prescription Before Age 21 
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Two other key areas lack clarity in relation to patterns of pediatric opioid 
prescribing. First is identification of what individual factors are associated with receipt of 
an opioid prescription as a young person. Some available data suggests that ethnic 
minority youth are less likely to receive an opioid for pain (Groenewald et al., 2015; 
Pletcher, Kertesz, Kohn, & Gonzales, 2008; Sadhasivam et al., 2012; Wu, Woody, Yang, 
Pan, & Blazer, 2011), despite reporting pain of greater intensities than Caucasian youth 
(Pletcher et al., 2008; Sadhasivam et al., 2012; Wu et al., 2011). Other data indicates that 
youth who are older (Groenewald et al., 2015), have a preexisting mental health diagnosis 
(Richardson et al., 2012; Welsh et al., 2017), or multiple pain complaints (Richardson et 
al., 2011) are more likely to receive an opioid or misuse opioids. Overall, the influence of 
other potentially important demographic and health-related variables requires further 
examination. It is also perplexing that although the prevalence of chronic pain is higher in 
female youth (King et al., 2011), research has not found significant differences in opioid 
prescribing rates to youth based on sex. In terms of misuse, however, one recent study 
with a non-clinical population did find that more males than females reported non-
medical opioid use (Osborne, Serdarevic, Crooke, Striley, & Cottler, 2017) and national 
rates of drug overdose death rates for males age 15-19 were higher than that of females  
(Curtain et al., 2017).  
Additionally, to our knowledge, there are no data available investigating how 
aspects of opioid dose or prescription frequency may influence health-related outcomes 
in youth. Specifically, there is a need to examine demographic and health-related factors 
in relation to the number of opioid prescriptions received (i.e., single versus multiple) and 
whether number of opioid prescriptions is associated with more problematic outcomes. 
This knowledge gap is significant because it is documented that opioid dependence and 
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withdrawal symptoms can be identified in children prescribed opioids after as little as 
seven days (Galinkin & Koh, 2014). Further, chronic opioid use (receipt of 3 or more 
prescriptions [Chou, Fanciullo, Fine, Adler, et al., 2009; Chou, Fanciullo, Fine, 
Miaskowski, et al., 2009; Portenoy, 1996]) in adults is associated with greater distress 
and disability, more frequent opioid misuse, and may be a risk factor in progression to 
heroin use (Chou, Fanciullo, Fine, Adler, et al., 2009; Dowell, Haegerich, & Chou, 2016; 
Højsted, Nielsen, Guldstrand, Frich, & Sjøgren, 2010; Kobus et al., 2012; Mars, 
Bourgois, Karandinos, Montero, & Ciccarone, 2014).  
Opioid Prescribing in a High-risk, Diverse state 
Opioid prescribing rates and overdose death rates vary significantly between 
states (Center for Disease Control, 2016; Centers for Disease Control and Prevention, 
2014). The State of New Mexico (NM) consistently has one of the highest rates of drug-
induced deaths, with 24.7 deaths per 100,000 people in 2015, 82% of which involved 
prescription opioids or heroin (New Mexico Department of Health, 2017). In NM youth, 
who comprise over one quarter of the state population (United States Census Bureau, 
2016), prescription opioids are the second most commonly used drug behind marijuana, 
with prevalence highest among males and those who identify as American Indian 
(Substance Abuse Epidemiology Section New Mexico Department of Health, 2016). 
From 2000 to 2014, overdose deaths in NM youth aged 0 to 24 years, largely from 
opioids, accounted for 8.5% of all overdose deaths in the state (Substance Abuse 
Epidemiology Section New Mexico Department of Health, 2016). In Albuquerque, the 
state’s largest city, a recent city-wide needs assessment of changes in opioid use and 
treatment availability reflected an increase in both nonmedical opioid use and in youth 
seeking treatment for problematic opioid use (Greenfield, Owens, & Ley, 2014). 
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Treatment agencies interviewed for this needs assessment shared clinical observations 
that youth, particularly those with chronic pain, are initiating use with prescriptions 
opioids and eventually switching to heroin to save money.  
Opioid Prescribing Practices in Pediatrics  
In 2015, the U.S. Food and Drug Association (FDA) approved the use of an 
opioid, OxyContin, for non-cancer pain treatment in pediatric patients age 11 to 16 years 
(U.S. Food and Drug Administration, 2015). Several sets of published guidelines exist for 
administration of opioids for chronic non-cancer pain treatment in adults (American 
Academy of Pain Medicine, American Pain Society, & American Society of Addiction 
Medicine, 2004; Chou, Fanciullo, Fine, Adler, et al., 2009; Costello, 2015; Dowell et al., 
2016), but there is a dearth of clear guidelines specifically for using opioids with youth. 
Delineating opioid prescription patterns in youth from preexisting data can illuminate 
areas of inconsistency, inequality, or inappropriate prescribing that may be useful in the 
development of pediatric opioid prescription guidelines which incorporate the dual goals 
of improving patient outcomes and minimizing risks of adverse consequences.  
The Current Study 
 For the current study, data were extracted from the University of New Mexico 
Hospital (UNMH) medical records system for all youth age 21 and under who received at 
least one outpatient opioid prescription between January 2005 and December 2016. The 
primary aim was to quantify trends in prescription of opioids to youth from 2005 to 2016 
in NM based on year, demographic, and medical variables. The secondary aims were to: 
1) identify individual factors associated with receipt of single or multiple prescriptions, 
and 2) examine outcomes following last opioid prescription, including markers of 
morbidity (e.g. receipt of a prescription for medication-assisted treatment) and mortality, 
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as well as identification of individual and medication characteristics associated with 
increased risk of experiencing an adverse outcome.  
 It was hypothesized that rate of opioid prescriptions to youth in NM would 
significantly increase from 2005 to 2016, and that differences in prescribing rates would 
be observed based on demographic (e.g. sex, ethnicity) and clinical (e.g. diagnosis) 
characteristics, consistent with the published literature. Regarding Aim 2, it was further 
hypothesized that only a small proportion of youth would receive more than one opioid 
prescription and that, consistent with the extant literature regarding differences in 
prescribing rates based on ethnicity, non-Hispanic Whites would be more likely to 
receive multiple opioid prescriptions in comparison to members of racial/ ethnic minority 
groups (Groenewald et al., 2015). Finally, based on trends in the adult literature (Hooten, 
St Sauver, McGree, Jacobson, & Warner, 2015), it was hypothesized that receipt of 
repeat or multiple prescriptions would be associated with increased rates of morbidity and 
mortality relative to single prescriptions.  
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Chapter 2 
Methodology 
Setting and Data Source 
Pre-existing data was extracted from the electronic medical records system at the 
University of New Mexico Hospital (UNMH). The hospital is located in an urban area, 
serves as New Mexico’s only Level 1 trauma center, and is the primary site of pediatric 
specialty care. Data were extracted and de-identified using the services of the UNMH’s 
Clinical Translational Science Center (CTSC). The CTSC team acts as an “honest 
broker” to evaluate patients in relation to stated inclusion criteria, extract the requested 
variables from the electronic health record (EHR), and de-identify patient health 
information (PHI) to safeguard confidentiality. The UNMH EHR was established in 
2005, thus, data extraction dates were from January 1, 2005 to December 31, 2016.  
Institutional Review Board approval was obtained to perform the data extraction 
and planned analyses detailed below. The study was deemed “Exempt” as data were pre-
existing and de-identified (Study approval ID: 16-123). 
Measures 
Inclusion criteria along with extracted variables in the dataset are presented in 
Table 1 and summarized below. Only encounters with opioid prescription dates within 
the study time frame were extracted and included.  
   Sample included patients age 0 to 21 years who received an outpatient 
prescription for an opioid between 2005 and 2016. Inpatient opioid prescriptions were 
excluded.  
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   Individual/ baseline demographic factors include relevant descriptive medical 
and psychosocial characteristics. These included age at first prescription encounter, race, 
ethnicity, and insurance payer status. 
     Opioid prescription variables were extracted for each outpatient visit where 
an opioid was prescribed in order to characterize aspects of the prescription and 
encounter (e.g. encounter location, active diagnoses). Type of opioid prescription was 
classified based on the active opioid agonist agent (e.g. oxycodone and 
acetaminophen/oxycodone were both classified as “oxycodone”): Oxycodone, 
Hydrocodone, Codeine, Tramadol, Morphine, Fentanyl, and Other (i.e. meperidine, 
opium products). Prescriptions for opioid antagonists (e.g., Methadone, Suboxone) were 
excluded, as they can be used for pain management or medication-assisted treatment of 
an opioid use disorder and medication indication was not always inferable from the data. 
A total of 99 individuals in the dataset received prescriptions for both an opioid agonist 
and an antagonist.  
The total number of opioid prescriptions received by each individual during each 
year of the data extraction period and over the course of the study timeframe was tallied 
to derive the total number of prescriptions. Furthermore, a binary variable was created to 
denote if individuals received single or multiple opioid prescriptions over the study 
period.  
 Outcomes variables were defined as markers of morbidity (overdose, receipt of a 
prescription for medication-assisted treatment) and mortality. 
 
 
Variable Extraction and Coding Methodology  
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Each case was assigned a unique ID number (in order to link patients across 
multiple encounters) and each prescription encounter was also assigned a unique ID by 
the CTSC. Frequency of opioid prescriptions across the study time frame was calculated 
for each patient into a “total opioid prescriptions” variable. A binary variable denoting 
individuals who received single versus multiple opioid prescriptions was also created.  
Patient age at first opioid prescription was calculated in years. Age at baseline was 
categorized into early childhood (0-5 years), school age (6-11 years), adolescent (12-17 
years), and young adult (18-21 years). Encounter location was coded as outpatient, 
emergency, discharge from inpatient, or day surgery. Insurance payer status was coded 
into three categories: Private/ Commercial, Public/ Government Assistance (e.g. 
Medicaid), and Uninsured.  
To examine outcomes following the patient’s most recent opioid prescription 
encounter, patients were tracked one year after their last opioid prescription. At each 
subsequent encounter, we looked for evidence of a prescription for medication-assisted 
treatment (MAT; i.e. suboxone) as a proxy for potential development of opioid 
dependency. The overdose and mortality variables were extracted from the patient’s 
entire medical history after receipt of an opioid. Additional descriptive variables were 
extracted for each overdose encounter, including documented substances at overdose and 
total number of overdoses.   
Diagnoses from encounters occurring on October 1, 2015 and later utilized ICD-
10 codes, due to a hospital wide transition; diagnoses from encounters prior to that date 
utilized ICD-9 codes. To integrate ICD-9 and ICD-10 diagnoses, coding of ICD-10 
chapters and subchapters was based on ICD-9 chapters and subchapters (as the majority 
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of cases had ICD-9 diagnosis), such that each ICD-10 diagnosis was grouped into the 
related ICD-9 chapter/ subchapter.  
Statistical Analysis Plan  
 Database merging, cleaning, and coding, was conducted using Excel and R (R 
Core Team, 2014) and analyses were conducted using SPSS v25 (IBM Corp. Released, 
2015). Descriptive statistics and frequencies were calculated for all sociodemographic, 
medical, medication, and outcome variables. Frequencies across time were calculated for 
opioid prescriptions, individuals receiving single versus multiple prescriptions, and 
markers of opioid-related morbidity and mortality. Relative risk, including 95% 
confidence intervals, was calculated for receipt of single versus multiple prescriptions, as 
well as markers of morbidity and mortality based on individual sociodemographic 
characteristics 
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Chapter 3 
Results 
From 2005-2016, 42,020 unique patients age 21 or younger received a total of 
71,647 opioid prescriptions. Table 2 provides an overview of annual frequency of opioid 
prescriptions as well as number of patients receiving single or multiple opioid 
prescriptions.  
Medication and Demographic Characteristics at Receipt of First Opioid (baseline) 
Medication Characteristics. The highest number of individuals received their 
first opioid prescription in 2008 (n=4,439), in contrast to 2005 when only 1,733 youth 
received an opioid prescription for the first time (see Table 3). Type of first opioid 
prescription was most commonly Oxycodone (46.0%, n=19,318) or Hydrocodone 
(36.5%, n=15,331), while few (<.1%, n=16) received Fentanyl as a first opioid 
prescription. We were unable to calculate Morphine Equivalent Dose (MED) for each 
prescription, as only a very small percentage of prescriptions (<20%) had adequate 
dosing information to calculate MED.  
Demographic characteristics. See Table 3 for demographic characteristics of 
patients. Mean age at receipt of first opioid prescription was 13.52 (sd = 6.50), although 
38.9% (n=16,327) of patients were young adults (age 18-21 years) at the time of their 
first prescription. The sample was primarily male (55.0%, n=23,093), of Hispanic/Latino 
ethnicity (50.1%, n=21,044), and most commonly reported races were White (48.3%, 
n=19,985) and American Indian/Alaskan Native (11.0%, 4,553), although 27.1% 
(n=11,241) of the sample declined to report their race or it was missing from the medical 
record. Patient primary language was English for most (88.9%, n=37,343), followed by 
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Spanish (8.9%, n=3,755). Half of the sample had public or government assisted health 
insurance (e.g., Medicaid; 50.1%, n=21,027).  
Encounter location. Location of first prescription encounter was most commonly 
in the emergency department (35.6%, n=14,954) or at discharge from inpatient care 
(29.4%, n=12,364). Opioid prescriptions were least likely to be prescribed in an 
outpatient clinic encounter (12.9%, n=5,401).  
Total opioid prescriptions. The majority of youth (68.80%, n=28,911) received 
only one opioid prescription during the study time frame, while 13,109 (31.20%) 
received two or more opioid prescriptions (see Table 3).  Of the patients who received 
multiple prescriptions, most received two (56.91%, n=7,460), but a marked 22.2% 
(n=2,915) received 4 or more opioid prescriptions.  
Non-opioid medications. Regarding other potentially interacting prescription 
drugs that were prescribed concurrently with the first opioid prescription, 
Benzodiazepines and Muscle Relaxants were most common, with 3.5% of the sample (n= 
1465) who had an active prescription for Benzodiazepines, 1.5% prescribed Muscle 
Relaxants (n=618), and 0.4% prescribed an SSRI or SNRI (n=163).  Individuals were 
rarely also prescribed anticonvulsants, tricyclic anti-depressants, or barbiturates (< .1%).  
 Presenting diagnoses. On average patients had 5.06 (sd = 5.41; range 1-64) 
presenting diagnoses tied to the encounter where the first opioid prescription was given; 
thus, baseline diagnoses are not mutually exclusive (see Table 4).  Diagnoses were most 
frequently from the ICD-9 chapters for “Injury and Poisoning” (most common diagnoses 
in this chapter were ‘fractures’) and “Supplementary Classification Of External Causes 
Of Injury And Poisoning’” chapters (most common diagnosis was ‘vehicle related 
injuries’).  More broadly, two thirds of diagnoses (67.8%) were coded as acute 
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conditions, 10.3% represented a chronic pain related condition (non-cancer), 2.6% were 
cancer related, 1.5% were for a mental health condition, and 10.3% indicated the 
presence of another non-pain related medical condition (e.g., metabolic disorders). 
Medication Characteristics and Prescribing Trends over Time 
From 2005 to 2016, overall frequency of opioid prescriptions increased by 
86.64% (from 2470 to 4620) with the largest increase (206.15%) observed from 2005 to 
2008 (2470 to 7562; see Figure 1 and Table 2). Prescribing rates trended downward 
from 2008 to 2016, decreasing by 39.04%.  
Number of patients receiving opioids per year increased by 95.10% across the 
study time frame (from 1736 patients in 2005 to 3387 patients in 2016; Figure 1 or Table 
2), with the largest increase (198.16%) occurring from 2005 to 2008, followed by a 
steady decrease in overall sample size through 2016 (-34.56%), mimicking trends in 
overall prescription frequency. 
 The raw number of patients receiving multiple prescriptions within a year 
increased from 391 in 2005 to 689 in 2016, but proportionally only increased from 
22.53% of the total sample in 2005 to a peak of 24.96% in 2008, followed by a decrease 
to 20.34% in 2016 (see Table 2). Thus, the highest number of patients received multiple 
prescriptions in 2008 (n=1292) and 2009 (n=1277). 
Opioid type. Regarding drug type, Oxycodone was consistently the most 
commonly prescribed opioid (e.g., OxyContin, Percocet; see Table 4). Overall rates of 
Oxycodone prescribing increased by 135.32% from 2005 (n=1192) to 2016 (n=2805), 
peaking in 2010 (n=3389). Tramadol prescriptions increased the most, marked by a 
487.5% increase across study time points (from n=16 to 94), including a 600% increase 
from 2005 to 2013 (from n=16 to 112). Prescription rates for Fentanyl also decreased by 
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50.0% across the study time points, but only after increasing by 140% from 2005 (n=10) 
to 2012 (n=24).  
Non-opioid medications. In 2016, almost twice as many individuals receiving 
their first opioid prescription also had an active prescription for a Benzodiazepine 
compared to 2005 (n=81 in 2005 and n=159 in 2016; 96.30% increase). Rates of other 
non-opioid medications remained stable over time.  
Receipt of Single versus Multiple Prescriptions  
 Relative risk of receiving multiple versus single opioid prescriptions significantly 
increased with age and when morphine or fentanyl was the first opioid prescription type 
(see Table 3). In particular, adolescents were 1.66 times more likely to receive multiple 
opioid prescriptions than children age 0-5 years (95% CI= 1.58-1.52). White, English-
speaking, not Hispanic/ Latino patients were also more likely to receive multiple opioid 
prescriptions.   
Opioid-related Adverse Outcomes 
 A summary of the frequency of adverse events is in Table 6 and illustrated in 
Figure 2. Broadly, large increases were observed in the frequency of adverse events from 
2005 to 2016: 2200% increases in incidents of mortality, 1400% increases in patients 
receiving medication-assisted treatment, and 1433% increases in overdose incidents. 
Over half of patients with documented adverse outcomes received multiple opioid 
prescriptions (51.76% of patients who experienced an overdose, 59.73% of patients 
receiving MAT, and 57.71% of patients who died), which is a higher percentage of 
patients receiving multiple opioid prescriptions than observed in the total sample 
(31.20%). 
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 Overdose. A total of 189 overdose incidents were reported for 170 individuals 
(see Tables 6 and 7), as indicated by overdose diagnoses, inpatient admission for 
treatment of overdose related symptoms, and/or administration of Naloxone. 
Proportionally, 0.45% of the entire sample experienced an overdose during 2005 to 2016, 
with the largest annual proportion of patients impacted in 2016 (1.36%) following a 
119.05% increase in overdose incidents from 2015 (n=21) to 2016 (n=46). A total of 149 
patients (87.60%; see Table 7) experienced 1 overdose, while 21 had two or more 
documented overdoses (12.49%). The majority of overdose incidents (98.40%; n=186) 
had documented involvement of an opioid (including both prescription opioids and 
heroin) in the encounter diagnoses, while 26.50% (n=50) had documentation of 
prescription opioids specifically. A total of 32 overdose incidents (16.93%) included 
documentation of active suicidal ideation or suicidal attempt via intentional overdose; SI 
was most commonly documented in overdose incidents occurring in 2006 (n=10). 
Medication-Assisted Treatment (MAT). The percentage of the entire sample 
who received a medication for the treatment of opioid dependence (e.g., buprenorphine, 
naltrexone, methadone, and buprenorphine-naloxone [Suboxone]) within 1 year of receipt 
of an opioid prescription increased from .06% in 2006 (n=1 out of 1736) to .44% in 2016 
(n=15 out of 3387), although was highest in 2014 (.58%; n=23 out of 3983).  
 Mortality. Data was extracted on all incidents of mortality for subjects in the 
study sample, not deaths only related to opioid use. Documented incidence of mortality in 
individuals prescribed an opioid increased from 2 individuals in 2005 to 46 in 2016 (from 
.12% of the sample to 1.39%), impacting a total of 201 patients. Similar to overdose 
incident rates, mortality incidents increased most significantly from 2015 (n=23) to 2016 
(n=46; an increase of 100%). Cause of mortality was unknown for most patients. On 
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average, deaths occurred 3.40 years (sd= 3.24; range 0-13 years) after receipt of the first 
opioid prescription.  
Differences in Outcomes Based on Medication and Individual Characteristics 
Table 8 includes a summary of medication-related and demographic 
characteristics of patients with documented markers of morbidity and mortality following 
receipt of an opioid prescription as well as relative risk of experiencing adverse outcomes 
based on these characteristics. Overall, increased risk for adverse outcomes differed 
significantly based on type of first opioid prescription, older age, minority status 
(specifically for mortality), encounter type, payer status, and receipt of multiple 
prescriptions.  
 Medication characteristics.  
 Year of first opioid. Patients who died or received MAT most commonly received 
their first opioid prescription in 2012 or earlier. Patients who experienced an overdose 
most commonly received their first opioid prescription from 2006- 2009, consistent with 
overall prescribing trends.  
 Type of first opioid prescription. Patients who experienced an overdose or 
received MAT were most commonly prescribed Oxycodone. Receipt of Morphine was 
associated with a 22.40-fold (95 CI=13.5-37.15) increased risk of receiving MAT and a 
64.39-fold increased risk of death (95% CI= 44.91-92.34) than Oxycodone. Similarly, the 
risk of receiving MAT or of mortality after receipt of a Tramadol prescription was 3.32 
times (95% CI= 1.23-8.96) and 32.63 times (95% CI= 8.75-121.69) greater than 
Oxycodone.  
 Encounter type. Patients receiving MAT and patients who died most commonly 
received their first opioid prescription during discharge from an inpatient admission 
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(39.60%, n=59; 42.20%, n=85, respectively). In relation to the total sample, 1.20% of the 
sample (n=65) who received an opioid prescription during an outpatient encounter died. 
Subsequently, relative risk for adverse outcomes was significantly reduced when 
receiving the first opioid prescription during an emergency, inpatient discharge, or day 
surgery encounter in comparison to outpatient encounters.  
 Frequency of opioid prescription. A larger proportion of patients receiving 
multiple opioid prescriptions experienced adverse outcomes as compared to patients who 
received only one opioid prescription. Most notably, of all patients who received 4 or 
more opioid prescriptions, 1.20% experienced an overdose (n=35), 1.48% received MAT 
(n=43), and 2.16% died (n=63). For comparison, 0.21-0.29% of all patients who received 
a single opioid prescription experienced an adverse outcome. Relative risk of adverse 
outcomes for individuals receiving multiple opioid prescriptions versus single 
prescriptions steadily increased as number of prescriptions increased. In particular, in 
patients who received 4 or more opioid prescriptions, the risk of overdose was 4.23 times 
greater (95% CI= 2.86-6.28), the risk of receiving MAT was 7.11 times greater (95% CI= 
4.81-10.50), and the risk of mortality was 7.35 times greater (95% CI=5.32-10.16).  
 Individual characteristics. 
 Age at first opioid prescription.  The majority of patients who experienced an 
overdose (94.12%, n=160) or received MAT (87.24%, n=130) received their first opioid 
prescription during adolescence (age 12-17 years) or as a young adult (age 18-21 years). 
Subsequently, adolescents and young adults were at increased risk of adverse events 
relative to youth age 11 and under, particularly overdose (RR=8.18, 95% CI= 4.32-15.49) 
and MAT (RR=3.50, 95% CI= 2.16-5.66). Age at first opioid prescription in patients who 
died was more varied: 32.34% (n=65) of deceased patients received their first opioid 
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prescription during adolescence, while 28.86% were age 0-5 years are receipt of first 
opioid (n=58). 
 Sex. Males were 1.35 times more likely to die (95% CI- 1.01-1.79) in comparison 
to females. Proportionally, more females than males received MAT (58.39%, n=87).   
 Ethnicity, Race, and Primary Language. Proportionally, within the entire 
sample, more racial minority patients died than white patients. Specifically, 4.34% 
(n=18) of all Asian patients, 2.17% of all Black/ Africa American patients, and 1.45% of 
American Indian/ Alaska Native patients died in comparison to 0.43% of all White 
patients; however, frequency of death was highest among White patients (42.29%, n=85) 
followed by American Indian/ Alaskan Native patients (32.84%, n=66). Additionally, 
relative risk of death was significantly greater in minority patients in comparison to 
White patients (3.41-10.20x greater). Equal proportions of the entire sample of 
Hispanic/Latino and Not Hispanic/Latino identifying patients died (.45% and .46%, 
respectively), although a greater frequency of deaths occurred in Hispanic/Latino patients 
(n=96, 46.27%, vs. n=53, 26.37%, of Non-Hispanic/Latino patients).  
 Overdose occurred most often in Hispanic/Latino (n=95, 55.89%, 0.45% of the 
total sample) and White patients (n=101, 59.42% of overdoses; 0.51% of the total 
sample. Similarly, Hispanic/Latino patients (n=90, 60.40%, 0.43% of the total sample) 
and White patients (n=91, 61.07%, 0.46% of the total sample) were more likely to receive 
MAT. Proportionally, within the entire sample, a marked 6.27% (n=26) of Asian patients 
received MAT and these patients were at 13.27 times higher risk (95% CI= 9.00-21.04) 
of receiving MAT compared to White patients. Primary language was English for nearly 
all patients experiencing adverse outcomes (87.56%- 96.79%), consistent with the full 
sample.  
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 Payer Status. Public/government assistance (e.g., Medicaid) was the most 
common type of insurance for patients experiencing all three outcomes (42.78%-
60.70%). Patients who were uninsured were 2.93 times more likely to experience an 
overdose (95% CI= 1.96-4.39) and 2.42 more likely to receive MAT (95% CI= 1.47-
4.01) when compared to privately insured patients.  
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Chapter 4 
Discussion 
The current study utilized pre-existing data drawn from the medical records 
system of a large university hospital to evaluate opioid prescription rates to youth in New 
Mexico (NM), as rates of prescription of opioids to children and adolescents at a 
statewide level were unknown. Further, individual factors and outcomes associated with 
receipt of single or repeat prescriptions and adverse outcomes were characterized to 
increase understanding of the prevalence and impact of opioid prescriptions. This large 
and comprehensive dataset captured several important variables, which allowed for 
examination of relations amongst hypothesized risk factors and opioid-related outcomes 
following the last opioid prescription. Unique aspects of this study are the racial and 
ethnic diversity of the sample, geographic location (rural, high-risk state for opioid 
use), utilization of hospital medical records data (rather than insurance claims data 
or data gathered via patient self-report), consideration of individual factors 
associated with receipt of multiple opioid prescriptions, and preliminary evaluation 
of longitudinal outcomes following receipt of an opioid prescription. 
Overall, substantial increases in prescription of opioids to youth in New Mexico 
as well as rates of opioid-related morbidity and mortality were observed. Despite 
downward trends in prescribing rates from 2008 to 2016, increases in opioid-related 
morbidity and mortality persisted. Patients who were older, White, not Hispanic/ Latino, 
and English-speaking were more likely to receive multiple opioid prescriptions, which is 
consistent with previous literature related to individual factors associated with receipt of 
any opioid (Groenewald et al., 2015; Pletcher et al., 2008; Sadhasivam et al., 2012; Wu et 
al., 2011), but not necessarily multiple opioids, as we are not aware of any preexisting 
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data in that domain. Increased risk of adverse outcomes was observed in patients 
receiving more than one opioid prescription, as well as patients who were older, of a 
minority racial background, publicly insured or uninsured, and who received Tramadol, 
Fentanyl, or Morphine as a first opioid prescription. Limitations of the current dataset did 
not allow for examination of some previously identified risk factors for opioid misuse in 
youth, including the presence of chronic pain, exposure to trauma, and other substance 
use (Groenewald, Law, Fisher, Beals-Erickson, & Palermo, 2019). A unique finding in 
this sample is that Asian patients, who comprised a small subset of the sample (1.0%) and 
represent a small subset of the overall population in New Mexico, had significantly 
proportionally higher rates of adverse events including much higher risk for receiving 
medication-assisted treatment (MAT) and death. 
Results from the present study suggest that prescription of opioids to youth in 
New Mexico is occurring with greater frequency in comparison to national prescribing 
trends, such as those reported by Groenewald et al. (2015). Interestingly, Groenewald et 
al. (2015) found that overall prescribing rates to youth in the United States remained 
stable and low, but significant increases in youth receiving 5 or more opioid prescriptions 
were observed. In contrast, rates of youth receiving multiple opioids in this dataset did 
not increase substantially over time. Thus, prescribing trends to youth in New Mexico 
appear more similar to adult prescribing trends in the US (Manchikanti et al., 2010; 
Shaheed et al., 2016; Vowles et al., 2015), particularly when examined in relation to the 
high rates of opioid-related morbidity and mortality. In line with national findings in 
adults, decreases in opioid prescribing within this sample did not equate to decreases in 
opioid-related morbidity and mortality (Centers for Disease Control and Prevention 
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National Center for Health Statistics, 2015; Jones et al., 2013; Rudd et al., 2016; Vowles 
et al., 2015).   
Although not explicitly captured in this dataset, there are several identified “risk 
factors” (Groenewald et al., 2019) for opioid misuse that are common among youth in 
New Mexico that likely make them more vulnerable to adverse outcomes and may 
explain differences in state versus national rates. Specifically, New Mexico consistently 
ranks as among the worst states for high rates of childhood trauma (a risk factor which 
has been linked to opioid use in adulthood (Groenewald et al., 2019)), including 
substance use in utero and high rates of infants born drug-dependent, as well as 
adolescent substance use (Gallagher et al., 2018). Geographically New Mexico is 
primarily rural and demographically, ethnically diverse. Previous work has identified 
adolescents living in rural areas as being at 35% greater odds of engaging in prescription 
opioid misuse (Monnat & Rigg, 2015) and high opioid prescribing rates have been 
recorded geographically in the southern United States (Rolheiser, Cordes, & 
Subramanian, 2018), but not NM in particular. Additionally, unmanaged pain has been 
repeatedly identified as a primary motive for nonmedical opioid use in adolescents (e.g. 
McCabe, West, & Boyd, 2013b). One potential driver of opioid prescribing and misuse 
rates in a rural state such as New Mexico could be difficulty accessing non-
pharmacological evidence-based pain management resources, due to geographic location 
and/or lack of availability of these resources. At this time, New Mexico does not have a 
specialized interdisciplinary pediatric pain rehabilitation program (American Pain 
Society, 2015), the gold standard of treatment for disabling chronic pain (Hechler et al., 
2015). Additionally, given that over a third of youth in New Mexico grow up in poverty, 
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several barriers may be present to traveling out of state for specialized treatment 
(Gallagher et al., 2018).  
While cause of death for patients in the sample is unknown, the large increase in 
mortality within the sample is perplexing and worrisome. Death rates in children and 
adolescents within the state have not increased, although, drug overdose deaths in New 
Mexico have risen since 2001 (Gallagher et al., 2018). Consistent with the present 
sample, American Indian youth in New Mexico die at more than twice the rate of other 
racial groups. Nationally, rates of adolescents dying from opioid-related complications 
are increasing, with a notable increase from 2014-2015 (Curtain et al., 2017). A notable 
subset of early childhood aged children died (age 0-5 years; n=58, .78% of the total 
sample of that age group). Since cause of death was unknown, it is hard to know if this 
may be related to accidental injury/ overdose of opioids or perhaps greater disease 
severity (e.g. cancer). Similarly, Fentanyl use with children is fairly rare, except during 
palliative care; thus it is recommended that the finding that youth prescribed Fentanyl 
were more likely to die should be interpreted with caution and within this clinical 
context, rather than in relation to rising Fentanyl-related death rates in the US.  
Increases in youth receiving medication-assisted treatment (MAT) for an opioid 
use disorder is a finding that comes with mixed implications. It is hard to know if this is 
reflective of an increase in incidence of opioid use disorders (OUD) or an increase in 
patients accessing treatment for an OUD; it is also unclear if MAT is being administered 
for prescription opioid dependency or heroin dependency. Increases in adolescents and 
young adults seeking MAT for an opioid use disorder further highlights previous findings 
(Greenfield et al., 2014) regarding the need to increase access to developmentally 
appropriate behavioral based treatments in conjunction with MAT in New Mexico. It is 
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well documented that patient abstinence and adherence rates while receiving MAT 
remain sub-optimal (Krupitsky et al., 2011; Ling et al., 2010; Mattick, Breen, Kimber, & 
Davoli, 2009; Resnick et al., 1992). For adolescents and young adults, in particular, 
developmentally appropriate behavioral treatments combined with MAT are 
recommended (COMMITTEE ON SUBSTANCE USE AND PREVENTION, 2016).  
Finally, results in the current study underscore previously documented relations 
between non-medical prescription opioid use and suicidal ideation (Divin & Zullig, 
2014), suggesting a need for interventions that address co-morbid mental health needs in 
concert with pain treatment. This finding also underscores the importance of safe storage 
and disposal of leftover opioids, as increased access to means for suicide increases risk of 
attempt and completion. Future research should carefully monitor suicidal ideation in 
youth prescribed an opioid to determine if the patient is at significant risk for intentional 
overdose. Relatedly, this work highlights the need for careful screening of identified 
factors associated with increased risk of adverse outcomes and risky use to inform opioid 
prescribing and prescription monitoring practices (e.g. CRAFFT [Knight, Sherritt, Shrier, 
Harris, & Chang, 2002; McCabe et al., 2012]). Additional measure development is 
needed in this area, however, to ensure that measures are valid and reliable in diverse 
populations and do not inappropriately restrict patients from adequate pain management.  
Limitations 
A feasible way to understand the evolution of opioid prescribing to youth and 
identify relevant individual characteristics is to examine existing data. A limitation of this 
approach is that data were not collected prospectively, nor was the database designed 
specifically to accomplish the study aims. Instead these data come from a clinical 
database which did not capture all variables of interest. The “real world” nature of these 
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data means that they still contain many relevant variables, and the retrospective aspect 
lends itself to immediate availability, perhaps offsetting this limitation. Further, the 
hospital data archives can only extract data from 2005 onwards, when the electronic 
medical record was implemented, naturally limiting the study timeframe. Thus, study 
aims could not be evaluated prior to that date. There is also no way to confirm whether or 
not opioid prescriptions were filled, if patients sought additional prescriptions from 
providers outside of the university hospital system, or if the first opioid prescription 
received during the study timeframe was truly the patient’s first exposure to being 
prescribed an opioid (e.g. patients may have received an opioid prescription before 2005). 
Frequency of adverse outcomes are also limited to those treated within the UNMH 
hospital system. Further, adverse events cannot be causally linked to receipt of an opioid 
prescription, however it is known that they occurred temporally after receipt of an opioid 
prescription. This dataset also likely only captures a subset of American Indian/ Alaska 
Native youth in New Mexico, as many AI/AN families in New Mexico receive care 
through Indian Health Services. Additionally, due to deidentification procedures, 
prescriptions dates could only be provided in years, rather than month and year and 
prescription start/ stop dates were not available; thus it was not possible to accurately 
calculate length of time between prescriptions. Finally, while it was intended to calculate 
Morphine Equivalent Dose (MED) to look at changes in dosing over time and 
associations with different baseline characteristics (e.g. race/ ethnicity), less than 20% of 
prescriptions had adequate data (e.g. dose and frequency) to calculate MED. Thus, we 
were unable to perform those analyses. It is also a limitation that a subset of patients 
declined to report or had missing values for race (27.1%) and/or ethnicity (22.5%). 
Conclusions and Significance  
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As life expectancy in the United States has declined for two years in a row, 
attributable largely to the increase in opioid overdose mortality among young adults and 
adults (Kochanek et al., 2017), the importance of quantifying opioid prescription rates to 
youth, a key access point for nonmedical use, and associated adverse outcomes cannot be 
overstated.  This is the first epidemiological study using hospital level data to examine 
opioid prescribing rates and associated longitudinal outcomes to children and adolescents 
in a high-risk state. Much of the available research on opioid prescribing rates to youth 
has been primarily derived from insurance claim databases (e.g. Groenewald et al., 2015; 
Richardson et al., 2011), rather than medical records data, limiting the clinical utility and 
generalizability of findings. Contributions from this research address several gaps in our 
understanding of opioid prescribing trends to children and adolescents including: 1) 
comprehensive quantitative measurement of prescribing rates of opioids to youth in New 
Mexico, 2) identification of individual factors in multiple domains associated with receipt 
of multiple opioid prescriptions and adverse outcomes 3) examination of prevalence of 
longitudinal outcomes (e.g. morbidity and mortality) after receipt of an opioid 
prescription.   
In particular, this study contributes to the growing literature base identifying 
factors associated with receipt of opioid prescriptions in youth and risk factors predictive 
of less favorable outcomes, including overdose and death. A new finding from this 
dataset is that, consistent with adult literature, receipt of more than one opioid 
prescription was associated with greater risk for opioid-related adverse consequences, 
highlighting potential additive risks of adverse outcomes when pediatric patients receive 
single versus multiple opioid prescriptions. This finding needs to be replicated in other 
samples of youth. Finally, the large difference in trends of opioid prescribing rates to 
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youth in New Mexico versus nationally indicates that national statistics may not be 
accurately representative of all states. In order to effectively and appropriately distribute 
intervention and treatment resources to the highest need areas, trends may need to be 
evaluated locally.  
 29 
 
Figure 1. 
Opioid prescribing trends over time in individuals who received single or multiple opioid prescriptions  
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Figure 2. 
Trends in adverse events in patients who received at least one opioid prescription 
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Table 1. 
Variables extracted from patient electronic medical records  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion criteria: Age 0-21, Prescribed an opioid during an outpatient encounter (e.g. Emergency Department, 
discharge from an inpatient admission, day surgery, or outpatient clinic) 
Exclusion criteria: Inpatient opioid prescription encounters 
Variables of interest 
Individual/ baseline 
Data extracted once for each 
patient 
Opioid prescription encounter  
Data extracted from each encounter 
where an opioid was prescribed  
Adverse outcomes  
Data extracted from each clinical 
encounter for 12 months following first or 
last prescription 
Age Medication-related characteristics: Markers of morbidity  
Sex      Encounter location      Overdose (admission, ED encounter) 
Ethnicity      Name of drug     Medication-Assisted Treatment  
Race           Prescribed dose Death 
Primary language      Duration/ dispense value Subsequent diagnoses 
Payer status      Total # of opioid prescriptions  
Non-opioid prescriptions       Number of years receiving   
     Other pain medications     multiple opioid prescriptions  
     Psychiatric medications Active diagnoses  
Premorbid diagnoses   
Note. An “encounter” is defined as a unique clinical instance of direct provider to patient interaction; Payer 
status= Public/ Government Assistance (e.g. Medicaid), Private, or Uninsured; Encounter location= Emergency, 
discharge from inpatient, outpatient, or day surgery; Diagnoses will also coded as Acute, Chronic pain, Mental 
Health, Other Co-Morbid Condition, or Cancer Related; Prescribed dose will be converted to Morphine 
Equivalent Dose.  
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Table 2.  
Annual sample characteristics including total opioid prescriptions and frequency of individuals receiving single vs. multiple 
prescriptions 
 
Year 
Total annual 
opioid 
prescriptions 
Total patients 
receiving their 
first opioid  
prescription* 
Total patients 
who received an 
opioid 
prescription** 
Patients who 
received a 
single opioid 
prescription 
Patients who 
received 
multiple opioid 
prescriptions 
% of sample 
receiving 
multiple opioid 
prescriptions 
2005 2470 1733 1736 1345 391 22.52% 
2006 5150 3431 3644 2830 814 22.34% 
2007 7000 4374 4864 3725 1139 23.42% 
2008 7562 4439 5176 3884 1292 24.96% 
2009 7487 4280 5124 3847 1277 24.92% 
2010 7215 4128 4980 3839 1141 22.91% 
2011 6974 3940 4846 3704 1142 23.57% 
2012 6295 3574 4452 3443 1009 22.66% 
2013 6203 3503 4337 3343 994 22.92% 
2014 5736 3153 3983 3081 902 22.65% 
2015 4945 2777 3470 2658 812 23.40% 
2016 4610 2688 3387 2698 689 20.34% 
TOTAL 71647 42020 49999 38397 11602 23.20% 
*Represents number of unique patient in the dataset. 
**This includes more patients than in the first column because some individuals received prescriptions in multiple years.  
Thus, each patient is counted only once per year, but may show up in multiple years. 
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Table 3. 
Medication-related and demographic characteristics at receipt of first opioid of patients who received single vs. multiple prescriptions 
 Full Sample 
N= 42,020 
Single opioid  
N=28,911 
Multiple opioid  
N= 13,109 
Relative risk for 
multiple opioids  
 N % N % N % (95% CI) 
Year of first prescription        
   2005† 1,733 4.1% 1047 3.6% 686 5.2% REF 
   2006 3,431 8.2% 2182 7.5% 1249 9.5% .92 (.85-.99) 
   2007 4,374 10.4% 2827 9.8% 1547 11.8% .89 (.83-.96) 
   2008 4,439 10.6% 2858 9.9% 1581 12.1% .90 (.84-.97) 
   2009 4,280 10.2% 2807 9.7% 1473 11.2% .87 (.81-.93) 
   2010       4,128 9.8% 2827 9.8% 1301 9.9% .80 (.74-.86) 
   2011 3,940 9.4% 2754 9.5% 1186 9.0% .76 (.71-.82) 
   2012 3,574 8.5% 2543 8.8% 1031 7.9% .73 (.67-.79) 
   2013 3,503 8.3% 2522 8.7% 981 7.5% .71 (.65-.77) 
   2014 3,153 7.5% 2315 8.0% 838 6.4% .67 (.62-.73) 
   2015 2,777 6.6% 2044 7.1% 733 5.6% .67 (.61-.73) 
   2016 2,688 6.5% 2185 7.6% 503 3.8% .47 (.43-.52) 
Total opioid prescriptions        
   1 28,911 68.8% 28,911 100% -- -- -- 
   2 7,460 17.8% -- -- 7,460 56.9% -- 
   3 2,734 6.5% -- -- 2,734 20.9% -- 
   4 or more 2,915 6.9% -- -- 2,915 22.2% -- 
First opioid prescription type        
   Oxycodone† 19,318 46.0% 12547 43.4% 6771 51.6% REF 
   Hydrocodone 15,331 36.5% 11120 38.5% 4211 32.1% .78 (.76-.81) 
   Codeine 6,907 16.4% 5006 17.3% 1901 14.5% .79 (.75-.82) 
   Tramadol 253 0.6% 154 0.5% 99 0.8% 1.12 (.96-1.30) 
   Morphine 150 0.4% 57 0.2% 93 0.7% 1.77 (1.56-2.01) 
   Fentanyl 16 <.1% 6 0.02% 10 0.01% 1.78 (1.22-2.61) 
   Other 45 .1% 21 0.1% 24 0.2% 1.52 (1.16-2.00) 
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 Full Sample 
N= 42,020 
Single opioid  
N=28,911 
Multiple opioid  
N= 13,109 
Relative risk for 
multiple opioids  
 N % N % N % (95% CI) 
Age 
   Early childhood (0-5 years) † 7,432 17.7% 5780 20.0% 1652 12.6% REF 
   School age (6-11 years) 6,790 16.2% 4829 16.7% 1961 15.0% 1.30 (1.23-1.37) 
   Adolescent (12-17 years) 11,471 27.3% 7240 25.0% 4231 32.3% 1.66 (1.58-1.52) 
   Young-adult (18-21 years) 16,327 38.9% 11,062 38.3% 5265 40.2% 1.45 (1.38-1.52) 
Sex         
   Female † 18,927 45.0% 12,974 44.9% 5,953 45.4% REF 
   Male 23,093 55.0% 15,937 55.1% 7,156 54.6% .99 (.96-1.01) 
Ethnicity        
   Not Hispanic/ Latino† 11,496 27.4% 7618 26.3% 3878 29.6% REF 
   Hispanic/ Latino 21,044 50.1% 14364 49.7% 6681 51.0% .94 (.91-.97) 
   Not reported 9,480 22.5% 6929 24.0% 2550 19.5% -- 
Race      
     White† 19,985 48.3% 13,239 46.5% 6746 52.2% REF 
     American Indian/Alaska Native 4553 11.0% 3144 11.0% 1409 10.9% .92 (.87-.96) 
     Black/African American 1292 3.1% 835 2.9% 457 3.5% 1.05 (.97-1.13) 
     Two or More Races 539 1.3% 372 1.3% 167 1.3% .92 (.81-1.04) 
     Asian 415 1.0% 313 1.1% 102 0.8% .73 (.61-.86) 
     Hawaiian Native/ Pacific Islander 96 0.2% 65 0.2% 31 0.2% .96 (.72-1.28) 
     Other 3295 8.0% 2579 9.1% 716 5.5% -- 
     Decline to answer/ unavailable 11,241 27.1% 7946 27.9% 3295 25.5% -- 
Primary language      
   English† 37,243 88.9% 25,455 88.3% 11,788 90.2% REF 
   Spanish 3,755 8.9% 2776 9.6% 979 7.5% .82 (.78-.87) 
   Other/ Not reported  894 2.1% 588 2.0% 306 2.3% -- 
Encounter type       
   Outpatient† 5,401 12.9% 3272 11.3% 2129 16.3% REF 
   Emergency 14,954 35.6% 11,017 38.1% 3937 30.0% .67 (.64-.70) 
   Discharge from inpatient 12,364 29.4% 7682 26.6% 4682 35.7% .96 (.92-1.00) 
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 Full Sample 
N= 42,020 
Single opioid  
N=28,911 
Multiple opioid  
N= 13,109 
Relative risk for 
multiple opioids  
 N % N % N % (95% CI) 
   Day surgery 9,301 22.1% 6940 24.0% 2361 18.0% .64 (.61-.68) 
Payer status      
    Private/ Commercial† 14,116 33.6% 9619 33.2% 4497 34.2% REF 
    Public/ Government assistance 21,027 50.1% 14,304 49.5% 6723 51.3% 1.00 (.97-1.04) 
    Uninsured 6863 16.3% 4981 17.2% 1882 14.4% .86( .82-.90) 
Non-opioid drugs         
   Benzodiazepines  1,465 3.5% 718 2.48% 747 5.70% -- 
   Muscle Relaxant 618 1.5% 394 1.36% 224 1.71% -- 
   SSRI/ SNRI 163 0.4% 74 0.26% 89 0.68% -- 
   Anticonvulsants 19 <.1% 10 0.03% 9 0.07% -- 
   Tricyclic anti-depressants 18 <.1% 7 0.02% 11 0.08% -- 
   Barbiturates 8 <.1% 5 0.02% 3 0.02% -- 
† Patients with this characteristic served as the reference group; CI denotes confidence interval; Bold values indicate 
statistically significant values based on the CI. RR for receiving multiple opioids in patients who also received non-
opioid drugs was not calculated, as there is not a hypothesis driven rationale for identifying a reference group.  
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Table 4.   
ICD-9 chapters for presenting diagnoses at encounter for first opioid prescription 
(baseline) 
 
ICD-9 Chapter N 
Injury And Poisoning 34,416 
Supplementary Classification Of External Causes Of Injury And Poisoning 18,142 
Supplementary Classification Of Factors Influencing Health Status And Contact 
With Health Services 12,152 
Symptoms, Signs, And Ill-Defined Conditions 10,998 
Diseases Of The Musculoskeletal System And Connective Tissue 10,224 
Diseases Of The Respiratory System 8333 
Diseases Of The Nervous System And Sense Organs 8205 
Diseases Of The Genitourinary System 4690 
Diseases Of The Digestive System 4320 
Complications Of Pregnancy, Childbirth, And The Puerperium 4012 
Congenital Anomalies 3662 
Diseases Of The Skin And Subcutaneous Tissue 1966 
Mental Disorders 1899 
Neoplasms 1869 
Diseases Of The Circulatory System 1713 
Diseases Of The Blood And Blood-Forming Organs 1360 
Endocrine, Nutritional And Metabolic Diseases, And Immunity Disorders 1252 
Infectious And Parasitic Diseases 484 
Certain Conditions Originating In The Perinatal Period 88 
 37 
Table 5. 
Frequency of opioid prescribing over time by type of opioid 
 
 
Opioid type 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 TOTAL 
Oxycodone 1192 2176 2876 3417 3609 3839 3453 3287 3162 3065 2958 2805 35839 
Hydrocodone 675 1859 2425 2316 2238 1958 2637 2379 2393 2192 1744 1530 24346 
Codeine 536 999 1589 1672 1441 1149 611 425 367 218 77 81 9165 
Morphine 28 60 33 42 102 146 125 64 95 106 43 75 919 
Tramadol 16 17 43 66 53 67 71 75 112 108 96 94 818 
Other 13 16 19 30 26 41 56 41 54 42 26 20 384 
Fentanyl 10 23 15 19 18 15 21 24 20 5 1 5 176 
Yearly Total 2470 5150 7000 7562 7487 7215 6974 6295 6203 5736 4945 4610 71647 
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Table 6.   
Frequency of markers of morbidity and mortality by year in patients who received single vs. multiple opioid prescriptions  
 
Year 
Total 
patients 
who 
received an 
opioid 
prescription 
Overdose Incidents Patients Receiving Medication- 
Assisted Treatment (MAT) 
Mortality Incidents 
Single* 
 
Multiple* 
 
Total  % of 
annual 
sample* 
Single* 
 
Multiple* 
 
Total  % of 
annual 
sample* 
Single* 
 
Multiple* 
 
Total % of 
annual 
sample* 
2005 1736 0 0 0 0% 0 1 1 0.06% 2 0 2 0.12% 
2006 3644 3 0 3 0.08% 2 4 6 0.16% 2 5 7 0.19% 
2007 4864 4 3 7 0.14% 0 3 3 0.06% 2 2 4 0.08% 
2008 5176 2 3 5 0.10% 3 7 10 0.19% 5 3 8 0.15% 
2009 5124 4 8 12 0.23% 3 8 11 0.21% 5 6 11 0.21% 
2010 4980 7 3 10 0.20% 6 7 13 0.26% 3 8 11 0.22% 
2011 4846 6 12 18 0.37% 5 8 13 0.27% 8 13 21 0.43% 
2012 4452 7 12 19 0.43% 13 11 24 0.54% 10 19 29 0.65% 
2013 4337 6 10 16 0.37% 10 9 19 0.44% 9 7 16 0.37% 
2014 3983 16 16 32 0.80% 12 11 23 0.58% 9 14 23 0.60% 
2015 3470 11 10 21 0.61% 4 7 11 0.32% 6 17 23 0.66% 
2016 3387 26 20 46 1.36% 2 13 15 0.44% 24 22 46 1.39% 
TOTAL --- 92 97 189 0.45%** 60 89 149 0.35%** 85 116 201 0.48%** 
*Denotes if the incident occurred in a patient who received single or multiple opioid prescriptions during the study timeframe.  
**Percentage of total sample was calculated out of 42,020, number of unique patients in the dataset.  
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Table 7.   
Characteristics associated with overdose incidents. 
 
Year Unique patients who 
experienced an 
overdose by year 
N=170* 
Total overdose 
incidents 
Documentation of active 
suicidal ideation or attempt via 
intentional overdose 
   2005 0 0 1 
   2006 3 3 10 
   2007 7 7 1 
   2008 5 5 3 
   2009 11 12 4 
   2010       9 10 2 
   2011 17 18 4 
   2012 19 19 1 
   2013 14 16 1 
   2014 29 32 1 
   2015 19 21 2 
   2016 37 46 2 
TOTAL * 189 32 
(16.93% of incidents) 
 
    
Documented substances at overdose         % N 
     Unspecified opioid 41.30% 78 
     Heroin 30.70% 58 
     Prescription opioids 22.80% 43 
     Prescription opioids & heroin 3.70% 7 
     Other substance 1.60% 3 
        
Total Number of Overdoses  % N 
     1 87.60% 149 
     2 9.40%% 16 
     3 1.80%% 3 
     4 1.20%% 2 
*Number of unique patients who experienced an overdose =170; since some patients 
experienced more than one overdose, they are counted in multiple years.  
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Table 8. 
Medication and demographic characteristics of patients with markers of morbidity and mortality after an opioid prescription 
 Overdose                            
 N= 170 
Medication-Assisted Treatment 
(MAT) N= 149 
Mortality                              
N= 201 
 N (% total 
sample) 
Relative Risk 
(95% CI) 
N (% total 
sample) 
Relative Risk    
(95% CI) 
N (% total 
sample) 
Relative Risk   
(95% CI) 
Year of first opioid        
 2005† 8 (.46%) REF 6 (.35%) REF 13 (.75%) REF 
 2006 29 (.85%) 1.83 (.84-4.00) 8 (.23%) 0.67 (.23-1.94) 26 (.76%) 1.01 (.52- 1.96) 
 2007 21 (.48%) 1.04 (.46-2.34) 11 (.25%) 0.73 (.27-1.96) 26 (.59%) 0.79 (.41-1.54) 
 2008 21 (.47%) 1.02 (.45-2.31) 9 (.20%) 0.59 (.21-1.64) 22 (.50%) 0.66 (.33-1.31) 
 2009 23 (.54%) 1.16 (.52-2.60) 21 (.49%) 1.42 (.57-3.51) 15 (.35%) 0.47 (.22-.98) 
 2010       22 (.53%) 1.15 (.51-2.69) 19 (.46%) 1.33 (.53-3.32) 22 (.53%) 0.71 (.36-1.41) 
 2011 12 (.30%) 0.66 (.27-1.61) 9 (.23%) 0.66 (.24-1.85) 21 (.53%) 0.71 (.36-1.41) 
 2012 10 (.28%) 0.61 (.24-1.53) 24 (.67%) 1.94 (.79-4.74) 21 (.59%) 0.78 (.39-1.56) 
 2013 8 (.23%) 0.49 (.19-1.32) 15 (.43%) 1.24 (.48-3.18) 8 (.23%) 0.30 (.13-.73) 
 2014 10 (.32%) 0.69 (.27-1.74) 12 (.38%) 1.10 (.41-2.92) 11 (.35%) 0.47 (.21-1.04) 
 2015 2 (.07%) 0.16 (.03-.73) 9 (.32%) 0.94 (.33-2.63) 9 (.32%) 0.43 (.19-1.01) 
 2016 4 (.15%) 0.32 (.10-1.07) 6 (.22%) 0.64 (.21-2.00) 7 (.26%) 0.35 (.14-.87) 
Total opioids       
 Single† 82 (.28%) REF 60 (.21%) REF 85 (.29%) REF 
 Multiple 88 (.67%) 2.37(1.75-3.20) 89 (.68%) 3.27 (2.36-4.54) 116 3.01 (2.27-3.97) 
 2 36 (.48%) 1.70 (1.15-2.52) 34 (.46%) 2.20 (1.44-3.34) 27 (36%) 1.23 (.80-1.90) 
 3 17 (.62%) 2.19 (1.30-3.69) 12 (.44%) 2.11 (1.14-3.93) 26 (.95%) 3.23 (2.09-5.01) 
 4 or more 35 (1.20%) 4.23 (2.86-6.28) 43 (1.48%) 7.11 (4.81-10.50) 63 (2.16%) 7.35 (5.32-10.16) 
First opioid type       
 Oxycodone† 107 (.55%) REF 92 (.48%) REF 74 (.36%) REF 
 Hydrocodone 47 (.31%) .55 (.39-.78) 24 (.16%) .33 (.31-.51) 46 (.30%) .78 (.54-1.13) 
 Codeine 12 (.17%) .31 (.17-.57) 11 (.16%) .33 (.18-.62) 40 (.58%) 1.51 (1.03-2.22) 
 Tramadol 3 (1.19%) 2.14 (.68-6.70) 4 (1.58%) 3.32 (1.23-8.96) 1 (.40%) 1.03 (.14-7.39) 
 Morphine 0 -- 16 (10.67%) 22.40 (13.5-37.15) 37 (24.67%) 64.39 (44.91-92.34) 
 Fentanyl 0 -- 0 -- 2 (12.5%) 32.63 (8.75-121.69) 
Age at first opioid         
 0-11 years† 10 (.07%) REF 19 (.13%) REF 94 (.66%) REF 
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 Overdose                            
 N= 170 
Medication-Assisted Treatment 
(MAT) N= 149 
Mortality                              
N= 201 
 N (% total 
sample) 
Relative Risk 
(95% CI) 
N (% total 
sample) 
Relative Risk    
(95% CI) 
N (% total 
sample) 
Relative Risk   
(95% CI) 
 AYA (12-21 years) 160 (.58%) 8.18 (4.32-15.49) 130(.47%) 3.50 (2.16-5.66) 107 (.38%) .58 (.44-.77) 
 0-5 years† 3 (.04%) REF 12 (.16%) REF 58 (.78%) REF 
 6-11 years 7 (.10%) 2.55 (.66-9.87) 7 (.10%) .62 (.25-1.62) 36 (.53%) .68 (.45-1.03) 
 12-17 years 39 (.34%) 8.42 (2.60-27.25) 39 (.34%) 2.11 (1.10-4.01) 65 (.57%) .73 (.51-1.03) 
 18-21 years 121 (.74%) 18.36 (5.84-57.71) 91(.56%) 3.52 (1.88-6.26) 42 (.26%) .33 (.22-.49) 
Sex         
  Female† 71 (.38%) REF 87 (.46%) REF 76 (.40%) REF 
  Male 99 (.43%) 1.14 (.84-1.55) 62 (.27%) .58 (.42-.15) 125 (.54%) 1.35 (1.01-1.79) 
Ethnicity        
 Not Hispanic/ Latino† 53 (.46%) REF  40 (.35%) REF 53 (.46%) REF 
 Hispanic/ Latino 95 (.45%) .98 (.70-1.37) 90 (.43%) 1.23 (.85-1.78) 93 (.45%) .97 (.70-1.36) 
 Not reported 24 (.25%) -- 19 (.20%) -- 55 (.19%) -- 
Race       
 White† 101 (.51%) REF 91 (.46%) REF 85 (.43%) REF 
 AI/AN 19 (.42%) .83 (.51-1.35) 17 (.37%) .82 (.49-1.37) 66 (1.45%) 3.41 (2.48-4.69) 
 Black/AA 15 (1.16%) 2.30 (1.34-3.94) 12 (.93%) 2.04 (1.12-3.71) 28 (2.17%) 5.10 (3.34-7.78) 
 Two or More Races 0 -- 0 -- 0 -- 
 Asian 33 (7.95%) 15.73 (10.75-23.0) 26 (6.27%) 13.7 (9.00-21.04) 18 (4.34%) 10.20 (6.19-16.80) 
 Hawaiian/ PI 0 -- 0 -- 0 -- 
 Other -- -- 0 -- 0 -- 
 Decline to answer 2 -- 3 (.03%) -- 4 (.04%) -- 
Primary language       
 English† 165 (.44%) REF 142 (.38%) REF 176 (.47%) REF 
 Spanish 3 (.08%) .18 (.06-.56) 0 -- 16 (.43%) .90 (.54-1.50) 
 Other/ Not reported  1 (.11%) -- 7 (.78%) -- 9 (.89%) -- 
 
Encounter type        
 Outpatient† 26 (.48%) REF 41 (.76%) REF 65 (1.20%) REF 
 Emergency 96 (.64%) 1.33 (.87-2.05) 44 (.29%) .39 (.25-.59) 31 (.21%) .17 (.11-.26) 
 Inpatient discharge 31 (.25%) .52 (.31-.88) 59 (.48%) .62 (.42-.93) 85 (.69%) .57 (.41-.79) 
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 Overdose                            
 N= 170 
Medication-Assisted Treatment 
(MAT) N= 149 
Mortality                              
N= 201 
 N (% total 
sample) 
Relative Risk 
(95% CI) 
N (% total 
sample) 
Relative Risk    
(95% CI) 
N (% total 
sample) 
Relative Risk   
(95% CI) 
 Day surgery 13 (.29%) .29 (.15-.56) 5 (.05%) .07 (.03-.18) 20 (.22%) .18 (.11-.29) 
Payer status       
 Private† 40 (.28%) REF 28 (.20%) REF 60 (.43%) REF 
 Public/Government 73 (.35%) 1.23 (.83-1.80) 88 (.42%) 2.11 (1.38-3.23) 122 (.58%) 1.37 (1.00-1.86) 
 Uninsured 57 (.83%) 2.93 (1.96-4.39) 33 (.48%) 2.42 (1.47-4.01) 18 (.26%) .62 (.36-1.04) 
† Patients with this characteristic served as the reference group; % of Total Sample is also known as “Absolute Risk”; CI denotes 
confidence interval; Bold values indicate statistically significant values based on the CI; AYA= Adolescents & Young Adults; AI/AN= 
American Indian/ Alaska Native; AA=African American 
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